In a recent article for Managed Healthcare Executive, editor Tracey Walker spoke with Trinity’s Jillian Godfrey Scaife about the findings of Trinity’s recent biosimilar whitepaper. In the article, Jillian highlights key takeaways from the findings. You can read the full story including further insights from Jillian here: http://bit.ly/2Br1FsD
Key findings from the report, which seeks to reveal opportunities to accelerate biosimilar adoption, include the following:
- Biosimilar pricing to date has not offered the sharp discounts payers expect, after accounting for contract discounts and nuances such as the “rebate trap”;
- Biologic innovators have taken legal and promotional actions that derail biosimilar commercial success;
- Providers are not fully comfortable with biosimilars and are interested in seeing more clinical and real-world data; if biosimilars were to attain interchangeability status, this gap in clinical comfort could be minimized
The report, conducted in partnership with Schlesinger Associates, is supported by findings from qualitative market research with medical directors at payer organizations in the United States. The findings are based on historical trends, current market dynamics, and future market access expectations in biosimilars.
“Biosimilar access still lags behind traditional small molecule markets, but there is so much potential for long-term cost savings for payer plans and the U.S. healthcare system as a whole,” said Neal Dunn, Partner, Trinity Partners. “Once interchangeability is achieved, other barriers such as clinical confidence and litigation will fall into place.”
“Each country’s commercial and regulatory landscape is nuanced based on laws, pay structures, and culture, which creates unique environments for market access,” said John Corcoran, Founder and President, Trinity Partners. “Our in-depth knowledge of the U.S. market provides us with unique insights that allow us to optimally navigate those channels to achieve market access as quickly as possible, thus providing treatments to patients who need them the most.”
To view the full research report, click here.
About Trinity Partners
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about Trinity Partners, click here.
John Greenaway, Jillian Scaife, Nick Simmons-Stern, Ali Haber, and Christina Danosi are traveling to Alexandria, Virginia this week to attend CBI’s Biosimilars Summit. At the conference, they’ll discuss how to overcome reimbursement hurdles in an expanding U.S. biosimilars market. Learn more about the event here: http://www.cbinet.com/conference/pc18014
Todd Foster, Trinity’s director of advanced analytics, will attend the PMSA’s Multi-Channel Marketing Symposium in Las Vegas, January 18 – 19 2018. During the event, Todd will meet with fellow industry leaders to discuss innovative marketing practices that use data to elevate multi-channel marketing for the biotechnology, medical and pharmaceutical industries. Learn more about the event here: http://bit.ly/2FIL3MS
In a recent article for Managed Healthcare Executive, reporter Mari Edlin spoke with Trinity’s John Corcoran about what he sees in the pipeline for 2018 in terms of drug affordability and pharma’s response to the matter. You can read the full article including further insights from John, here: http://bit.ly/2DHZpwg
In a recent article for Formulary Watch, editor Christine Blank spoke with Trinity’s Leslie Sandberg Orne about new blockbuster drugs to hit the marketplace in 2018 that will treat HIV, diabetes, cancer, migraine headaches and other conditions. Check out Leslie’s insights in the full article, here: http://bit.ly/2ArPeZz
On December 9th, Trinity’s Herman Sanchez, Alex Chiang and Vivian DeWoskin attended the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA. During the meeting, Trinity employees had the opportunity to receive insight on evidence-based practice and decision making around malignant and non-malignant hematology, as well as the controversies associated with diagnosis and management. A full agenda of the annual meeting
can be found here: http://bit.ly/2zCT0Q5
Our Managing Partner Dave Fitzhenry recently sat down with Brian Orelli from BioWorld Insight where he discussed the findings of our second annual Drug Index. In the article titled, “Winners and losers from the FDA approval class of 2014,” Dave provided a comprehensive overview of the commercial success and performance of each individual drug humorously highlighting how Trinity Partners “envisioned it like looking at NFL draft grades.”
A team of experts from Trinity Partners and Janssen have published an article in Dermatology and Therapy. The paper, titled, “Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis,” describes the results of a study to determine dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. The study concluded that comprehensive education regarding treatment attributes may help minimize the influence of subjective biases and facilitate appropriate and patient-centered treatment selection in psoriasis.
The paper was authored by Gordon Lau, Gretchen R. Chiu, Nandini Hadker, Aparna Deshpande, Stephen Fleming, and Nicola Vance, all of Trinity Partners, along with Seina Lee and Steve Fakharzadeh of Janssen Scientific Affairs. At the time of the study, Matthew Alcusky was a postdoctoral fellow with Thomas Jefferson University and Janssen Scientific Affairs.
To view the full text of the article, please visit http://bit.ly/2hJqe9k
Trinity Partners is proud to officially announce the promotion of Krista Perry and John Greenaway to the role of Principal and to Trinity Partners’ Leadership Team. In their new roles, Krista and John will co-lead Trinity Partners’ San Francisco office and consulting team. They will also partner with other Leadership Team members to drive business development and deliver projects to assist west coast biopharmaceutical clients in optimizing their strategic business decisions, commercial planning, and analytics. Further, both Krista and John continue to support the development and training of managers and junior staff.
A graduate of Dartmouth College, Krista Perry joined Trinity Partners in 2006 and has been serving clients as a project manager since 2013. Krista works in the general strategy consulting group and focuses on commercial assessments, prioritizations and launch planning. She has a focus on commercial support for clients focusing on rare diseases, including significant experience working with Trinity’s primary market research group to conduct qualitative and quantitative global research studies with physicians, patients, advocacy groups, payers and other stakeholders in orphan markets.
In addition to her vast experience in rare disease, Krista has broad experience in women’s health. Last year, she led a pro-bono project for the Bill and Melinda Gates Foundation, helping them assess the potential of a collection of maternal vaccines. Krista has been with Trinity Partners for 11 years.
John Greenaway, a graduate of the University of Michigan and Northwestern University’s Kellogg School of Management, joined Trinity Partners in 2010. As part of the strategy consulting team, John supports the consulting and advisory needs for key pharmaceutical and medical device clients and their commercial executives. John provides senior pharmaceutical executives with analytics-based strategic recommendations in forecasting, market opportunity assessments, licensing and acquisition, and product launch planning.
John co-leads for Trinity’s Pricing, Access, Reimbursement, and Contracting (PARC) service, supporting pharmaceutical companies developing market access strategies and implementing pricing, contracting, and patient support programs. In this role, John has spoken and been a panel moderator at several industry conferences. Notably, John has presented Trinity’s published papers “Innovative Contracting Solutions in a Changing Healthcare Landscape” and “Changes to Medical Benefit Reimbursement and Implications for Drug Contracting and Pricing.” Additionally, he has moderated industry panels on “Best Practices to Develop and Implement Effective Pricing and Contracting Strategies.”
“Krista and John are leaders in the Trinity community, contributing to some of the most critical projects in the Strategy Consulting group,” said Dave Fitzhenry, Managing Partner at Trinity Partners. “Both principals truly deserve this recognition, as they are not only experts in what they do, but also genuine team players. As Trinity continues to grow, we are looking forward to seeing how Krista and John evolve in their new roles.”
About Trinity Partners
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here.